Koers Summit Therapeutics plc London S.E.
Aandelen
GB00BN40HZ01
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 2,46 mld. 3,08 mld. 2,86 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | - | Nettowinst (verlies) 2025 * | - | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 11,88% |
Recentste transcriptie over Summit Therapeutics plc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mahkam Zanganeh
CEO | Chief Executive Officer | 52 | 11-11-20 |
Robert Duggan
CEO | Chief Executive Officer | 79 | 01-12-19 |
Director of Finance/CFO | 46 | 01-12-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Duggan
CEO | Chief Executive Officer | 79 | 01-12-19 |
Robert Booth
BRD | Director/Board Member | 70 | 28-09-22 |
Director of Finance/CFO | 46 | 01-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,96% | 105 mld. | |
-1,43% | 104 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |